PARP1 and ovarian carcinoma: Since the approval of the first PARP inhibitor, Olaparib, for the treatment of BRCA1/2-mutated ovarian cancer in 2014, this class of drugs has expanded to include several others, such as rucaparib, niraparib, and talazoparib, each with varying pharmacokinetic properties and clinical applications [8,9].